EMEA-000694-PIP03-17
Key facts
| Invented name |
Forxiga
|
| Active substance |
dapagliflozin
|
| Therapeutic area |
Cardiovascular diseases
|
| Decision number |
P/0202/2018
|
| PIP number |
EMEA-000694-PIP03-17
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Prevention of cardiovascular events in patients with chronic heart failure
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
AstraZeneca AB (UK)
Tel. +44 2037496236 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|